(OTCBB: OVIT) is a drug development company engaged in the development and commercialization of targeted cancer therapies. OncoVista produces innovative drug discovery, registration strategies and emerging technologies, allowing the company to bring to market less toxic and highly effective anti-cancer drugs. The company engages in the development and commercialization of targeted cancer therapies through the acquisition of rights to technologies and drugs and through the development of proprietary products.
OncoVista intends to identify, develop and rapidly commercialize innovative therapies for safer and more efficacious treatments of cancer. The Company’s primary therapeutic strategy is based on treating the patient’s tumor(s) with therapies that will be selective based upon specific biochemical characteristics of the cancer cells comprising the tumor. The Company believes that the development of targeted approaches to the administration of anticancer agents will lead to improved efficacy and/or reduced toxicity.
In targeting compounds for acquisition and development, OncoVista focuses on candidates that have been previously tested in human clinical trials or animal models, as well as technologies that may improve the delivery or targeting of previously tested, and in some cases marketed, anticancer agents. The Company intends to develop their key candidates into novel, highly efficacious therapies to be marketed by means of corporate alliances.
The combination of OncoVista’s extensive in-house pre-clinical and clinical expertise with our global drug development network will lead to rapid and cost-effective regulatory approval and commercialization of novel therapies for the treatment of cancer. The Company will realize revenues through licensing/milestone fees and royalties flowing from out-licensing/partner agreements. OncoVista will market and commercialize their drugs through strategic partnerships with leaders in the oncology market.